Charilaos Gerasimou1, Georgia Phaedra Vitali1, George D Vavougios2,3, Charalabos Papageorgiou4, Athanasios Douzenis1, Styliani I Kokoris4, Ioannis Liappas5, Emmanouil Rizos6. 1. Second Department of Psychiatry, Attikon General Hospital, National & Kapodistrian University of Athens, Medical School, Athens, Greece. 2. Department of Respiratory Medicine, University of Thessaly, School of Medicine, Larissa, Greece. 3. Athens Naval Hospital, Neurology Clinic, Athens, Greece. 4. Laboratory of Hematology and Blood Transfusion Department, Attikon General Hospital, National & Kapodistrian University of Athens, Medical School, Athens, Greece. 5. First Department of Psychiatry, Eginition Psychiatric Hospital, National & Kapodistrian University of Athens, Medical School, Athens, Greece. 6. Second Department of Psychiatry, Attikon General Hospital, National & Kapodistrian University of Athens, Medical School, Athens, Greece erizos@med.uoa.gr.
Abstract
BACKGROUND: Clozapine is a second-generation antipsychotic drug used in treatment-resistant schizophrenia. Fever induced by clozapine is a rather frequent side-effect which usually occurs in the first 4 weeks of treatment. Despite its effectiveness, there are potentially life-threatening adverse effects, such as cardiotoxicity. CASE REPORT: We present the case of a 31-year-old caucasian male with refractory schizophrenia who developed benign fever, increase of C-reactive protein and high troponin levels, without presenting any other signs to myocarditis, on the 13th day under clozapine treatment, which declined progressively upon discontinuation of the drug. DISCUSSION: This case hints at the presence of initially subclinical cardiotoxicity as an underlying factor in patients developing fever. CONCLUSION: Taking advantage of more sensitive methods for measuring troponin, clinicians would be promptly aware of this possible side-effect. This would allow for significant reduction of the risk of cardiac dysfunction, further attained by carefully monitoring the patient. Copyright
BACKGROUND:Clozapine is a second-generation antipsychotic drug used in treatment-resistant schizophrenia. Fever induced by clozapine is a rather frequent side-effect which usually occurs in the first 4 weeks of treatment. Despite its effectiveness, there are potentially life-threatening adverse effects, such as cardiotoxicity. CASE REPORT: We present the case of a 31-year-old caucasian male with refractory schizophrenia who developed benign fever, increase of C-reactive protein and high troponin levels, without presenting any other signs to myocarditis, on the 13th day under clozapine treatment, which declined progressively upon discontinuation of the drug. DISCUSSION: This case hints at the presence of initially subclinical cardiotoxicity as an underlying factor in patients developing fever. CONCLUSION: Taking advantage of more sensitive methods for measuring troponin, clinicians would be promptly aware of this possible side-effect. This would allow for significant reduction of the risk of cardiac dysfunction, further attained by carefully monitoring the patient. Copyright
Authors: Kathlyn J Ronaldson; Paul B Fitzgerald; Andrew J Taylor; Duncan J Topliss; John J McNeil Journal: Aust N Z J Psychiatry Date: 2011-04-27 Impact factor: 5.744
Authors: Michael Kluge; Andreas Schuld; Alexander Schacht; Hubertus Himmerich; Mira A Dalal; Peter M Wehmeier; Dunja Hinze-Selch; Thomas Kraus; Ralf W Dittmann; Thomas Pollmächer Journal: Psychoneuroendocrinology Date: 2008-10-04 Impact factor: 4.905
Authors: Yue Wu; Jieqiang Zhu; Peter Fu; Weida Tong; Huixiao Hong; Minjun Chen Journal: Int J Environ Res Public Health Date: 2021-07-03 Impact factor: 3.390